



Daniel M. Silver
Partner
T. 302-984-6331
F. 302-691-1260
dsilver@mccarter.com

McCarter & English, LLP
Renaissance Centre
405 N. King Street, 8th Floor
Wilmington, DE 19801-3717
www.mccarter.com

February 14, 2022

VIA CM/ECF

The Honorable Leonard P. Stark
United States District Court for the District of Delaware
J. Caleb Boggs Federal Building
844 N. King Street
Unit 26, Room 6124
Wilmington, DE 19801-3555

Re: AstraZeneca Pharmaceuticals LP v. Becerra, et al., C.A. No. 21-27-LPS

Dear Judge Stark:

We write on behalf of AstraZeneca to alert this Court of further developments relevant to the Court's disposition of the litigation.

As the Court is aware, several Administrative Dispute Resolution (ADR) petitions have been filed against AstraZeneca and have been assigned to panels for formal proceedings. On January 7, 2022, the parties filed a Joint Status Report informing the Court that AstraZeneca had sought to stay those ADR proceedings pending (*inter alia*) the decision in this case. The ADR petitioners opposed AstraZeneca's stay motions.

Today, February 14, an ADR panel denied AstraZeneca's stay motion, per the attached opinion. In so ruling, the panel stated that it "respects the role of Article III courts in our constitutional system and will abide by any orders issued by such courts," Op. at 3, but the panel expressly rejected AstraZeneca's argument that the panel should await this Court's decision on the parties' fully briefed summary judgment motions before engaging AstraZeneca in ADR proceedings. The panel ordered AstraZeneca to respond to the petition by March 13.

Respectfully, AstraZeneca continues to believe that an expeditious resolution of this matter is appropriate, and indeed, necessary in view of the progression of parallel proceedings.

Respectfully submitted,

/s/ Daniel M. Silver

Daniel M. Silver (#4758)

cc: All Counsel of Record (via CM/ECF and E-Mail)